Parkinson’s disease is a progressive neurological disorder that primarily impairs movement control. It results from the slow degeneration of dopamine-producing neurons in the brain, particularly in the substantia nigra, a region crucial for managing voluntary motor function. According to estimates by DelveInsight, there were 2.7 million diagnosed prevalent cases of Parkinson’s disease in the 7MM in 2023, with the United States accounting for around 45% of these cases. XADAGO, marketed as EQUFINA in some regions, is a selective MAO-B inhibitor used as an add-on treatment for Parkinson’s disease patients experiencing “off” episodes while on a stable dose of levodopa. The drug’s unique dual mechanism of action – MAO-B inhibition and modulation of glutamate release – offers both dopaminergic and non-dopaminergic effects, positioning it as a differentiated product in the PD adjunctive therapy landscape. In the U.S. and Europe, XADAGO/EQUFINA has faced stiff competition from generic MAO-B inhibitors (like selegiline and rasagiline) and newer Parkinson’s disease therapies, including COMT inhibitors, dopamine agonists, and extended-release levodopa formulations. Despite this, its favorable safety profile and once-daily dosing have supported its uptake in certain patient segments, especially in Europe. Market penetration has been slower in the U.S. due to both reimbursement hurdles and physician preference for more established adjunctive treatments. However, XADAGO/EQUFINA has demonstrated stronger market performance in Asia, particularly in Japan and South Korea, due to focused commercial strategies and a high unmet need for effective “off time” management. Meiji Seika Pharma and Eisai, the regional marketing partners, have successfully leveraged the drug’s differentiated profile in clinician education, leading to growing adoption among neurologists. The global market dynamics for XADAGO/EQUFINA are shaped by a mix of competitive intensity, regional adoption trends, and payer dynamics. Looking ahead, the manufacturer’s ability to expand into new geographies, secure favorable reimbursement, and differentiate against both generics and newer entrants will be critical. Moreover, as Parkinson’s disease treatment moves toward more personalized approaches, XADAGO/EQUFINA may find sustained relevance in specific subpopulations, particularly those requiring a balance of efficacy and tolerability. The Parkinson’s disease market in the 7MM was valued at USD 3.2 billion in 2023, with the market expected to grow over the forecast period (2020-2034), fueled by the launch of new therapies, increasing prevalence, better access to healthcare, and rising demand for more advanced and effective treatment options. In addition to XADAGO/EQUFINA, emerging competitors of XADAGO/EQUFINA include Solengepras (Cerevance), Minzasolmin (UCB Biopharma SRL/Novartis), Buntanetap (Annovis Bio), and others. Buntanetap has successfully completed Phase III trials for early-stage Parkinson’s disease, while Annovis Bio has scheduled a meeting with the FDA in Q1 2025 to determine the development path forward for Buntanetap in the treatment of Parkinson’s disease. Key milestones of XADAGO/EQUFINA include the US FDA approval of XADAGO in March 2017, the European Union approval of XADAGO in February 2015, and the launch of EQUFINA in Japan in November 2019. The report also highlights the historical and forecasted sales of XADAGO/EQUFINA from 2020 to 2034, segmented into the 7MM. The product profile, clinical development, and market assessment are also discussed in the report. Table 1: XADAGO/EQUFINA Product Profile
| **Product Profile** | **Description** |
| — | — |
| Active Ingredient | Safinamide |
| Dosage Form | Film-coated oral tablet |
| Strength | 50 mg and 100 mg |
| Manufacturer | Newron Pharmaceuticals/Eisai/Meiji Seika Pharma |

The report provides an in-depth analysis of the XADAGO/EQUFINA market, highlighting its strengths and weaknesses relative to competitors. It also provides insights into the emerging competitors of XADAGO/EQUFINA and the market dynamics shaping the global Parkinson’s disease treatment landscape. **Market Drivers and Barriers:**
* Market drivers:
+ Increasing prevalence of Parkinson’s disease
+ Growing demand for effective treatment options
+ Improved access to healthcare
+ Rising demand for more advanced and effective treatment options
* Market barriers:
+ Stiff competition from generic MAO-B inhibitors and newer therapies
+ Reimbursement hurdles in the U.S. + Physician preference for more established adjunctive treatments
**SWOT Analysis:**
* Strengths:
+ Unique dual mechanism of action
+ Favorable safety profile
+ Once-daily dosing
* Weaknesses:
+ Stiff competition from generic MAO-B inhibitors and newer therapies
+ Reimbursement hurdles in the U.S. * Opportunities:
+ Expanding into new geographies
+ Securing favorable reimbursement
+ Differentiating against both generics and newer entrants
* Threats:
+ Increased competition from emerging competitors
+ Changes in market dynamics and payer dynamics

Emerging Competitors of XADAGO/EQUFINA

Buntanetap, developed by Annovis Bio, has successfully completed Phase III trials for early-stage Parkinson’s disease. Annovis Bio has scheduled a meeting with the FDA in Q1 2025 to determine the development path forward for Buntanetap in the treatment of Parkinson’s disease. Solengepras, developed by Cerevance, has completed Phase III trials and is expected to report topline data in the first half of 2026. Minzasolmin, developed by UCB Biopharma SRL/Novartis, is currently in Phase II clinical trials. These emerging competitors will provide new options for patients with Parkinson’s disease, and their development will have a significant impact on the global Parkinson’s disease treatment landscape.

Parkinson’s Disease Treatment Landscape

The Parkinson’s disease treatment landscape is complex and rapidly evolving. The introduction of new therapies, increasing prevalence, and rising demand for more advanced and effective treatment options are driving the market forward. XADAGO/EQUFINA is a significant player in this landscape, offering a unique dual mechanism of action and a favorable safety profile. However, stiff competition from generic MAO-B inhibitors and newer therapies, as well as reimbursement hurdles in the U.S., pose challenges to its growth. The manufacturer’s ability to expand into new geographies, secure favorable reimbursement, and differentiate against both generics and newer entrants will be critical in maintaining XADAGO/EQUFINA’s position in the market.

XADAGO/EQUFINA Market Insight Report

The XADAGO/EQUFINA market insight report provides an in-depth analysis of the market, highlighting its strengths and weaknesses relative to competitors. * Clinical development and market assessment of XADAGO/EQUFINA. * Market drivers and barriers shaping the global Parkinson’s disease treatment landscape. * SWOT analysis of XADAGO/EQUFINA. The report provides a comprehensive understanding of the Parkinson’s disease treatment landscape and the role of XADAGO/EQUFINA in this landscape.

DelveInsight Report

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. The XADAGO/EQUFINA market insight report is one of the company’s extensive portfolio of reports on the Parkinson’s disease market. The report provides an in-depth analysis of the market, highlighting its strengths and weaknesses relative to competitors. The company supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. DelveInsight has a subscription-based platform that provides hassle-free access to all the healthcare and pharma market research reports. DelveInsight is headquartered in San Francisco, California, and has a team of experts in life sciences, including pharmacology, biotechnology, and market research. The company provides a range of services, including market research, business consulting, and regulatory affairs support.

Contact Us

For more information about DelveInsight and its reports, please contact:
Shruti Thakur
info@delveinsight.com
+14699457679
Visit DelveInsight’s website: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
The company’s website provides a range of reports on the Parkinson’s disease market, including the XADAGO/EQUFINA market insight report.

XADAGO/EQUFINA Market Potential

The XADAGO/EQUFINA market potential report provides an in-depth analysis of the market, highlighting its strengths and weaknesses relative to competitors.

XADAGO/EQUFINA Pipeline

The XADAGO/EQUFINA pipeline report provides an in-depth analysis of the pipeline, highlighting its strengths and weaknesses relative to competitors.

XADAGO/EQUFINA Epidemiology

The XADAGO/EQUFINA epidemiology report provides an in-depth analysis of the epidemiology, highlighting its strengths and weaknesses relative to competitors.